Navigation Links
Trophos Publishes ALS Article in Journal of Pharmacology and,Experimental Therapeutics

Trophos Describes Identification, Characterization and Broad Neuroprotective Properties of TRO19622 in Journal of Pharmacology and Experimental Therapeutics

Neurodegenerative Disease Specialists Publish Details of a Novel Drug Candidate for ALS That Targets Mitochondrial Proteins

MARSEILLE, June 19th, 2007 - Trophos SA, a biopharmaceutical company specializing in the discovery and development of drugs for neurological disorders, announced today that a publication entitled "Identification and characterization of TRO19622 (cholest-4-en-3-one, oxime), a novel drug candidate for amyotrophic lateral sclerosis" has been accepted and published online May 11, 2007 in the Journal of Pharmacology And Experimental Therapeutics (J Pharmacol. Exp. Ther. 2007 May 11; [Epub ahead of print]).

Amylotrophic lateral sclerosis (ALS), more commonly known as Lou Gehrig's disease in the USA, is a progressive and fatal neurological disease that is estimated to affect about 100,000 people worldwide. There is no cure for ALS. The only drug approved for ALS is riluzole (Rilutek(R), Sanofi-Aventis), which has been demonstrated to confer some survival benefit to ALS patients.

The studies reported in the paper by Bordet et al., (see below) identify two protein targets of TRO19622 present in the outer mitochondrial membrane suggesting that the compound has potential in a range of additional commercially attractive therapeutic indications involving mitochondrial dysfunction, including painful neuropathies. The publication describes the models of motor neuron disease employed to support the use of this compound to treat ALS, as well as spinal muscular atrophy. TRO19622 is currently in a Phase IIa clinical trial to establish its efficacy as a treatment for painful diabetic neuropathy.

TRO19622 is representative of novel compounds identified using the proprietary neuronal cell screening platform developed at Tr
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from Human Clinical Trials for New Cancer Drug
2. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
3. The Lancet Publishes PREVAIL Study Results Showing Lovenox Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke
4. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
5. Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
6. Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
7. Medical Journal Publishes First Large-Scale Survey Revealing Experiences of IPF Patients
8. Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
9. Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal
10. JACC Publishes Long-Term Safety and Tolerability Data from Ranolazine Open Label Experience (ROLE) Program
11. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease

Post Your Comments:
(Date:11/20/2009)..., , NEW YORK, Nov. 20 /PRNewswire-FirstCal...s today contributing to a transformation in Americ...paradigm that is already delivering higher quality...curve downward -- making medicine smarter for the ...mpany today explained how the elements in its stra...
(Date:11/20/2009)..., , NEW YORK, Nov. 20 ...t research report is available in its catalogue. ,...Forecasts to 2015 ,, http://www.reportlinker...sis-and-Forecasts-to-2015.html#utm_source=prnewswi... ,, Description ,, India Medical Equipment...
(Date:11/20/2009)..., , MINNEAPOLIS, Nov. 20 /PRNewswire-FirstCa...unced results for its first quarter ended Septembe... per diluted share, on revenues of $3,263,000. Th...per diluted share, on revenues of $3,168,000 for t... the first quarter results, Biotel President and C...
Breaking Medicine Technology:Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost 2Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost 3Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost 4Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost 5Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 2Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 3Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 4Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 5Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 6Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 7Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 8Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 9Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 10Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 11Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 12Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 13Biotel Announced Profitable First Quarter Ended September 30, 2009 2Early initiation of Arctic sea ice formation 9271 1Early initiation of Arctic sea ice formation 9271 2Early initiation of Arctic sea ice formation 9271 3Pulmonx Announces New President and CEO Michael A Baker to Lead Interventional Pulmonology Company 51853 1Pulmonx Announces New President and CEO Michael A Baker to Lead Interventional Pulmonology Company 51853 2Pulmonx Announces New President and CEO Michael A Baker to Lead Interventional Pulmonology Company 51853 3Grubb 26 Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 51851 1Grubb 26 Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 51851 2Grubb 26 Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 51851 3
... Company extension to address remaining questions ...pplication, IRVINE, Calif., Jan. 25 IDM Pharma, ...pany recently presented to the,Committee for Medic...,committee of the European Medicines Evaluation Ag... Application (MAA) for mifamurtide (L-MTP-PE) for,...
...Va., Jan. 25 A report released,today by The Cornu...new,additives placed in infant formula are serious...orns and toddlers., The report, ,Replacing Mother...etails research questioning the alleged benefits o...laboratories and extracted from,algae and fungus, ...
Other Medicine Technology:IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival 2IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival 3IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival 4IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival 5Infant Formula Manufacturers Again under Ethical Cloud: 'Marketing Gimmick' Linked to Serious Illnesses 2Infant Formula Manufacturers Again under Ethical Cloud: 'Marketing Gimmick' Linked to Serious Illnesses 3
(Date:11/20/2009)...o Understanding Brain Wiring and Diseases ,, WA...eremy Schmahmann, Professor of Neurology at Harvar...tts General Hospital in Boston, on Thursday, Novem... new field of study called "Connectivity" at the l...mann is an award-winning leader in the field of th...
(Date:11/20/2009)...gressmen in Competitive Re-election Battles Could ... Washington, DC (Vocus) November...re-election next year in races deemed to be compet...regret voting for House Speaker Nancy Pelosi&rsquo... International/ O’Leary Report poll. (The ...
(Date:11/20/2009)...RNewswire-USNewswire/ -- Samuel Gladding is no Scr...eans to be "happy" during the holidays. As a licen...ily counseling and chair of the Department of Coun...search shows that it is the pressure to be happy t...ing the holidays. ,, That,s why he,s challengin...
(Date:11/20/2009)... with chronic kidney disease often fail to detect ...increasing a child,s risk for serious heart proble...ren,s Center and other institutions. A report of t...can Society of Nephrology. , Researchers compa...gular doctor visits to readings obtained via a spe...
(Date:11/20/2009)...n with seasonal flu , , FRIDAY, Nov. 20...rting that children with asthma are more likely to...u. , "Asthma has been identified as a significa...fluenza, present in 21 percent to 30 percent in th...w researchers from the Hospital for Sick Children ...
Breaking Medicine News(10 mins):Health News:MINDlink Foundation Launches to Connect the Cerebellum to Cures 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 3Health News:Why Holidays Don't Have To Be 'Happy' 2Health News:High blood pressure easy to miss in children with kidney disease 2
...re Platform-HealthRules(R)-Poised to ...GTON, Mass., April 22 HealthEdge, the leading,pro...stration, business,intelligence and portal softwar...ure capital and private equity firm., "We believe...
..., Will Earn a 16 Percent Patient Share in the Bip...eport from Decision Reso...es, one of the,world,s leading research and adviso...nd has both antimanic and antidepressant,effects w...
...gency Services, a,division of Omnicom Group Inc. (...lthcare and pharmaceutical agencies Cline Davis Ma...of the Year Awards at the 19th Annual,Manny Awards...mpetition in Category II (agencies with $10 millio...
...ida,Pharmaceuticals, Inc. (OTC Bulletin Board: AID...-focused corporate synopsis on its English,languag...e downloaded as a,pdf document. The synopsis detai...re growth avenues., About Aida Pharmaceuticals, ...
...3-Minute,Press Show is a daily video program hoste...ws air Monday through Friday on:, http://tv.wallst...-Minute Press Show features in-depth interviews wi...st,recent press release, and its impact on the com...
...ollege of Allergy,Asthma & Immunology (ACAAI) rece... surveys that highlight the importance of improvin...survey findings and other important,information fo...g the dialogue about unmet needs for patients with...
Other Medicine News:Health News:HealthEdge Receives $13 Million Investment Commitment to Fund Significant Growth 2Health News:A Drug That Carries a Lower Risk of Weight Gain Than AstraZeneca's Seroquel and Has Antimanic and Antidepressant Effects Would Earn a 30 Percent Patient Share in Bipolar Disorder Treatment 2Health News:Omnicom's Diversified Agency Services Healthcare Agencies Top Med Ad News' Manny Awards 2Health News:Aida Pharmaceuticals, Inc. Announces Availability of Downloadable Corporate Synopsis on its Website 2Health News:Featured Stocks on Today's Edition of WallSt.net's 3-Minute Press Show: CYRX, RHWI 2
Automatic Tangent Screen
Focus Toric Monthly lenses
...Made Toric soft contact lenses let you enjoy a lev...ns in a lens custom made to fit your eye., Th...y PC Technology™, which creates a unique mat...C), a substance found naturally in human cell memb...
Hydrasoft® Toric
Medicine Products: